Tiago Biachi de Castria, Medical Oncologist, Associate Member at Moffitt Cancer Center, Associate Professor at University of South Florida, shared a post on LinkedIn:
“Phase 1 trial with MOMA-341 is now open at Moffitt (NCT06974110)! This is a potent WRN helicase inhibitor with great preclinical activity in MSI-H tumors and a great option for our GI cancers patients with primary or acquired resistance to IO.”
More posts featuring Tiago Biachi de Castria on OncoDaily.